Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388): Results of a randomized clinical trial

Charles L M Olweny, Tom Toya, Edward Katongole‐Mbidde, Stephen K. Lwanga, Raphael Owor, Sebastian Kyalwazi, Charles Vogel

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Previous trials at our Institute revealed the effectiveness of actinomycin‐D and vincristine in the treatment of Kaposi's Sarcoma. We herein report the results of a further randomized trial designed to test the efficacy of the three‐drug combination consisting of actinomycin‐D, vincristine and imidazole carboxamide and to compare the results with those obtained by combining actinomycin‐D and vincristine only for all forms of Kaposi's Sarcoma. Of the 40 patients treated with two drugs, 22 (55%) achieved complete tumour regression, 13 (32.5%) had partial response and 5 (12.5%) did not respond. On the other hand, 30 out of 32(94%) of those receiving three drugs had complete tumour regression, one had partial and one had no response. There is a significantly higher complete response rate (p<0.002) in the group receiving three drugs than in that receiving two drugs. The side effects encountered were comparable.

Original languageEnglish (US)
Pages (from-to)649-656
Number of pages8
JournalInternational Journal of Cancer
Volume14
Issue number5
DOIs
StatePublished - 1974
Externally publishedYes

Fingerprint

Dacarbazine
Kaposi's Sarcoma
Vincristine
Randomized Controlled Trials
Pharmaceutical Preparations
Therapeutics
Neoplasms
imidazole

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388) : Results of a randomized clinical trial. / Olweny, Charles L M; Toya, Tom; Katongole‐Mbidde, Edward; Lwanga, Stephen K.; Owor, Raphael; Kyalwazi, Sebastian; Vogel, Charles.

In: International Journal of Cancer, Vol. 14, No. 5, 1974, p. 649-656.

Research output: Contribution to journalArticle

Olweny, Charles L M ; Toya, Tom ; Katongole‐Mbidde, Edward ; Lwanga, Stephen K. ; Owor, Raphael ; Kyalwazi, Sebastian ; Vogel, Charles. / Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388) : Results of a randomized clinical trial. In: International Journal of Cancer. 1974 ; Vol. 14, No. 5. pp. 649-656.
@article{90b9e8cc788a41eb993499a7e9516fde,
title = "Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388): Results of a randomized clinical trial",
abstract = "Previous trials at our Institute revealed the effectiveness of actinomycin‐D and vincristine in the treatment of Kaposi's Sarcoma. We herein report the results of a further randomized trial designed to test the efficacy of the three‐drug combination consisting of actinomycin‐D, vincristine and imidazole carboxamide and to compare the results with those obtained by combining actinomycin‐D and vincristine only for all forms of Kaposi's Sarcoma. Of the 40 patients treated with two drugs, 22 (55{\%}) achieved complete tumour regression, 13 (32.5{\%}) had partial response and 5 (12.5{\%}) did not respond. On the other hand, 30 out of 32(94{\%}) of those receiving three drugs had complete tumour regression, one had partial and one had no response. There is a significantly higher complete response rate (p<0.002) in the group receiving three drugs than in that receiving two drugs. The side effects encountered were comparable.",
author = "Olweny, {Charles L M} and Tom Toya and Edward Katongole‐Mbidde and Lwanga, {Stephen K.} and Raphael Owor and Sebastian Kyalwazi and Charles Vogel",
year = "1974",
doi = "10.1002/ijc.2910140512",
language = "English (US)",
volume = "14",
pages = "649--656",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388)

T2 - Results of a randomized clinical trial

AU - Olweny, Charles L M

AU - Toya, Tom

AU - Katongole‐Mbidde, Edward

AU - Lwanga, Stephen K.

AU - Owor, Raphael

AU - Kyalwazi, Sebastian

AU - Vogel, Charles

PY - 1974

Y1 - 1974

N2 - Previous trials at our Institute revealed the effectiveness of actinomycin‐D and vincristine in the treatment of Kaposi's Sarcoma. We herein report the results of a further randomized trial designed to test the efficacy of the three‐drug combination consisting of actinomycin‐D, vincristine and imidazole carboxamide and to compare the results with those obtained by combining actinomycin‐D and vincristine only for all forms of Kaposi's Sarcoma. Of the 40 patients treated with two drugs, 22 (55%) achieved complete tumour regression, 13 (32.5%) had partial response and 5 (12.5%) did not respond. On the other hand, 30 out of 32(94%) of those receiving three drugs had complete tumour regression, one had partial and one had no response. There is a significantly higher complete response rate (p<0.002) in the group receiving three drugs than in that receiving two drugs. The side effects encountered were comparable.

AB - Previous trials at our Institute revealed the effectiveness of actinomycin‐D and vincristine in the treatment of Kaposi's Sarcoma. We herein report the results of a further randomized trial designed to test the efficacy of the three‐drug combination consisting of actinomycin‐D, vincristine and imidazole carboxamide and to compare the results with those obtained by combining actinomycin‐D and vincristine only for all forms of Kaposi's Sarcoma. Of the 40 patients treated with two drugs, 22 (55%) achieved complete tumour regression, 13 (32.5%) had partial response and 5 (12.5%) did not respond. On the other hand, 30 out of 32(94%) of those receiving three drugs had complete tumour regression, one had partial and one had no response. There is a significantly higher complete response rate (p<0.002) in the group receiving three drugs than in that receiving two drugs. The side effects encountered were comparable.

UR - http://www.scopus.com/inward/record.url?scp=0016280275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016280275&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910140512

DO - 10.1002/ijc.2910140512

M3 - Article

C2 - 4617713

AN - SCOPUS:0016280275

VL - 14

SP - 649

EP - 656

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -